发明名称 Treatment of tumors using specific anti-L1 antibody
摘要 The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
申请公布号 US9260521(B2) 申请公布日期 2016.02.16
申请号 US201314045019 申请日期 2013.10.03
申请人 MEDIGENE AG;DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTS 发明人 Kelm Daniela;Altevogt Peter;Moldenhauer Gerhard;Breitling Frank;Krueger Achim;Baerreiter Silke;Luettgau Sandra;Moebius Ulrich;Li Yi;Sebens Susanne;Schaefer Heiner
分类号 C07K16/00;C12P21/08;A61K39/395;A61K39/00;C07K16/28;A61K45/06;A61N5/02;A61N5/06;A61N5/10;G01N33/574 主分类号 C07K16/00
代理机构 The Marbury Law Group, PLLC 代理人 The Marbury Law Group, PLLC
主权项 1. A purified binding molecule capable of binding L1CAM (i) comprising the following six CDR sequences RASQDISNYLN (SEQ ID No: 1), YTSRLHS (SEQ ID No: 2), QQGNTLPWT (SEQ ID No: 3), RYWML (SEQ ID No: 4), EINPRNDRTNYNEKFKT (SEQ ID No: 5), and GGGYAMDY (SEQ ID No: 6), or (ii) which is capable of binding to the same L1CAM epitope recognized by the monoclonal antibody 9.3, produced by the hybridoma cell deposited under DSMZ ACC2841, or (iii) comprising the following six CDR sequences QDISNY (SEQ ID No: 7), YTS, QQGNTLPWT (SEQ ID No: 8), GYTFTRYW (SEQ ID No: 9), INPRNDRT (SEQ ID No: 10), and ALGGGYAMDY (SEQ ID No: 11), wherein the purified binding molecule capable of binding L1CAM is selected from the group consisting of single chain antibody (scFv), a multimer of scFv, a diabody, a triabody, a tetrabody, an antigen-binding fragment of a monoclonal antibody, a Fab, a tandab, a flexibody, a bispecific antibody, and a chimeric antibody.
地址 Martinsried DE